[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338016-105":59,"doc-detail-338016-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pathology-of-surgically-resected-lung-cancers-following-neoadjuvant-therapy-review","Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy - Review","","Non-small cell lung cancer is often diagnosed at an advanced but resectable stage, and adding systemic treatment improves outcomes versus surgery alone in locally advanced disease. Chemo-immunotherapy in the (neo)adjuvant setting is now a standard for patients without targetable mutations. This review updates current guideline approaches to histologic regression grading after neoadjuvant therapy and discusses emerging controversies in specimen evaluation, weighted versus unweighted methods, tumor-type cut-offs, and lymph node assessment after immunotherapy and targeted therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pathology-of-surgically-resected-lung-cancers-following-neoadjuvant-therapy-review/338016/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pathology-of-surgically-resected-lung-cancers-following-neoadjuvant-therapy-review/338016.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pathology important in evaluating neoadjuvant therapy for resectable lung cancer?","Question",{"text":112,"@type":113},"Neoadjuvant therapy allows an immediate assessment of treatment effect on resected tissue. This highlights the role of pathology in clinical decision-making and research.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does regression grading refer to after neoadjuvant therapy?",{"text":117,"@type":113},"Regression grading is the histologic evaluation of treatment effect, summarized as guidelines for histological assessment after neoadjuvant therapy (also called regression grading).",{"name":119,"@type":110,"acceptedAnswer":120},"How is major pathologic response (MPR) defined in this review?",{"text":121,"@type":113},"MPR is defined as ≤ 10% residual viable tumor (RVT). It is used as a surrogate endpoint, potentially improving trial efficiency and accelerating advances.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338016,1791272149,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Pathology of Surgically Resected Lung Cancers Following  \nNeoadjuvant Therapy  \nSabina Berezowska, MD,* Mark Keyter, MD,* Hasna Bouchaab, MD,† and  \nAnnikka Weissferdt, MD‡§  \nAbstract: In around 30% of patients, non-small cell lung cancer is diagnosed at an advanced but resectable stage. Adding systemic therapy has shown clear beneﬁt over surgery alone in locally advanced disease, and currently, chemo-immunotherapy in theadjuvant or neoadjuvant setting is the new standard for patients without targetable mutations. One major advantage of the neoadjuvant approach is the possibility of an immediate evaluation of the treatment effect, highlighting the role of pathology as an important contributor at the forefront of clinical decision-making and research. This review provides a summary and an update on current guidelines for histological evaluation of treatment effect after neoadjuvant therapy, also known as regression grading, and discusses newer data focusing on areas of evolving questions and controversies, such as the gross examination of the tumor and tumor bed, weighted versus unweighted evaluation approaches, discussion of histologic tumor type-speciﬁc cut-offs for major pathologic response, assessment of lymph nodes and regression grading after immunotherapy and targeted therapy. As no data or recommendations exist on regression grading of multiple tumor nodules, a practical approach is recommended. Lastly, we will touch on additional tissue biomarkers and summarize recent advances in the ardently discussed ﬁeld of using circulating tumor DNA for the evaluation of treatment response.  \nKey Words: NSCLC, neoadjuvant treatment, regression grading (Adv Anat Pathol 2024;31:324–332)  \nINTRODUCTION AND CLINICAL RATIONALE BEHIND NEOADJUVANT THERAPY  \nNon-small cell lung cancer (NSCLC) comprises 80% of lung cancer diagnoses, and in the pre-screening era, patients still present most frequently in advanced stages of the disease. In around 30% of patients, the tumor is resectable but locally advanced, and the addition of systemic chemotherapy to resection has proven beneﬁcial, with a 5% gain in  \nFrom the *Department of Laboratory Medicine and Pathology, Institute of Pathology; †Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland;‡Department of Pathology and Laboratory Medicine; and §Department of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston.  \nNo speciﬁc funding was received for the preparation of this manuscript.  \nThe authors have no funding or conﬂicts of interest to disclose.  \nReprints: Sabina Berezowska, MD, Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, 1011 Lausanne, Switzerland (e-mail: sabina.berezowska@chuv.ch) .  \nAll ﬁ[gures can be viewed online in color at www.anatomicpathology.com](gures can be viewed online in color at www.anatomicpathology.com).  \nCopyright © 2024 The Author(s) . Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nDOI: 10.1097/PAP.0000000000000441  \n[324](324 | www.anatomicpathology.com)[ |](324 | www.anatomicpathology.com)[ www.anatomicpathology.com](324 | www.anatomicpathology.com)  \noverall survival (OS) in both the adjuvant and neoadjuvant chemotherapy setting.1–3 Systemic therapy has evolved, with currently chemo-immunotherapy as the new standard for patients without targetable mutations, due to clearly superior outcome results. Three randomized trials have recently conﬁrmed the superiority of adding immunotherapy to the standard of care (neo)adjuvant chemotherapy. Addition of ","cbCaieBomH1HrbQb","https://ap.wps.com/l/cbCaieBomH1HrbQb","pdf",1007674,"English","# Abstract\n# Introduction and Clinical Rationale Behind Neoadjuvant Therapy\n## Rationale for neoadjuvant systemic therapy\n## Pathologic response as an endpoint","[{\"question\":\"Why is pathology important in evaluating neoadjuvant therapy for resectable lung cancer?\",\"answer\":\"Neoadjuvant therapy allows an immediate assessment of treatment effect on resected tissue. This highlights the role of pathology in clinical decision-making and research.\"},{\"question\":\"What does regression grading refer to after neoadjuvant therapy?\",\"answer\":\"Regression grading is the histologic evaluation of treatment effect, summarized as guidelines for histological assessment after neoadjuvant therapy (also called regression grading).\"},{\"question\":\"How is major pathologic response (MPR) defined in this review?\",\"answer\":\"MPR is defined as ≤ 10% residual viable tumor (RVT). It is used as a surrogate endpoint, potentially improving trial efficiency and accelerating advances.\"}]","Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy - Review | PDF",1790021587,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ccd2295dad7ce4f61d7da9da73d2802.webp",983,1363,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e472090f0e8ae99f9542cf5ca45b4d90.webp",982,1362,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b13c8d7a35d874857b623da6ec27b859.webp",981,1361,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13ea99b98046bee5adaba1f612728cd5.webp",980,1359]